BrainStorm (BCLI) retains PharmaNet to assist in Development of Protocol for FDA Approval
BrainStorm Cell Therapeutics Inc., a developer of adult stem cell technologies and central nervous system (CNS) therapeutics, has signed an agreement with PharmaNet LLC, a global drug development services provider, to help Brainstorm develop protocol and IND file for submission to the U.S. FDA for approval of BrainStorm’s amyotrophic lateral sclerosis (ALS) in human clinical trials. The FDA has already granted Orphan Drug Designation for BrainStorm’s NurOwn™ treatment for ALS, and the company’s deal with PharmaNet brings the company one step closer to receiving FDA approval for human clinical trials in the United States. Dr. Joyce L. Frey-Vasconcells will head…